Cross-Sector entity
SNDL is most often covered alongside B. Riley Financial, which appears in 3 of these 3 stories. The clearest coverage concentration is market-trends: 1 of 3 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
SNDL is most often covered alongside B. Riley Financial, which appears in 3 of these 3 stories. The clearest coverage concentration is market-trends: 1 of 3 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each. SNDL appears in 3 tracked Cross-Sector stories from August 4, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SNDL. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
